372 related articles for article (PubMed ID: 19401703)
1. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.
Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; London WB; Cohn SL; Pearson AD; Maris JM
Br J Cancer; 2009 May; 100(9):1471-82. PubMed ID: 19401703
[TBL] [Abstract][Full Text] [Related]
2. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Cohn SL; Pearson AD; London WB; Monclair T; Ambros PF; Brodeur GM; Faldum A; Hero B; Iehara T; Machin D; Mosseri V; Simon T; Garaventa A; Castel V; Matthay KK;
J Clin Oncol; 2009 Jan; 27(2):289-97. PubMed ID: 19047291
[TBL] [Abstract][Full Text] [Related]
3. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
Schleiermacher G; Mosseri V; London WB; Maris JM; Brodeur GM; Attiyeh E; Haber M; Khan J; Nakagawara A; Speleman F; Noguera R; Tonini GP; Fischer M; Ambros I; Monclair T; Matthay KK; Ambros P; Cohn SL; Pearson AD
Br J Cancer; 2012 Oct; 107(8):1418-22. PubMed ID: 22976801
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
Owens C; Irwin M
Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
[TBL] [Abstract][Full Text] [Related]
5.
Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
J Clin Pathol; 2023 Sep; 76(9):599-605. PubMed ID: 35414524
[TBL] [Abstract][Full Text] [Related]
6. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
[TBL] [Abstract][Full Text] [Related]
7. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract][Full Text] [Related]
9. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D; Vo KT; London WB; Fischer M; Ambros PF; Nakagawara A; Brodeur GM; Matthay KK; DuBois SG
Cancer; 2016 Mar; 122(6):935-45. PubMed ID: 26709890
[TBL] [Abstract][Full Text] [Related]
10. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
11. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma in adolescents: genetic and clinical characterisation.
Castel V; Villamón E; Cañete A; Navarro S; Ruiz A; Melero C; Herrero A; Yáñez Y; Noguera R
Clin Transl Oncol; 2010 Jan; 12(1):49-54. PubMed ID: 20080471
[TBL] [Abstract][Full Text] [Related]
13. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
14. Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.
Scaruffi P; Parodi S; Mazzocco K; Defferrari R; Fontana V; Bonassi S; Tonini GP
Mol Diagn; 2004; 8(2):93-100. PubMed ID: 15527323
[TBL] [Abstract][Full Text] [Related]
15. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System.
Naranjo A; Irwin MS; Hogarty MD; Cohn SL; Park JR; London WB
JCO Clin Cancer Inform; 2018 Dec; 2():1-15. PubMed ID: 30652588
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG).
Ohira M; Nakamura Y; Takimoto T; Nakazawa A; Hishiki T; Matsumoto K; Shichino H; Iehara T; Nagase H; Fukushima T; Yoneda A; Tajiri T; Nakagawara A; Kamijo T
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053166
[TBL] [Abstract][Full Text] [Related]
17. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
Monclair T; Brodeur GM; Ambros PF; Brisse HJ; Cecchetto G; Holmes K; Kaneko M; London WB; Matthay KK; Nuchtern JG; von Schweinitz D; Simon T; Cohn SL; Pearson AD;
J Clin Oncol; 2009 Jan; 27(2):298-303. PubMed ID: 19047290
[TBL] [Abstract][Full Text] [Related]
18. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Kao PC; Naranjo A; Kamijo T; Ramanujachar R; London WB; DuBois SG
Pediatr Blood Cancer; 2023 Feb; 70(2):e30054. PubMed ID: 36316811
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
